Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. DT&CRO Co's Net Income for the
three
months ended in Mar. 2026 was ₩-13,778 Mil. DT&CRO Co's Revenue for the
three
months ended in Mar. 2026 was ₩10,127 Mil. Therefore, DT&CRO Co's net margin for the quarter that ended in Mar. 2026 was -136.04%.
The historical rank and industry rank for DT&CRO Co's Net Margin % or its related term are showing as below:
XKRX:383930'
s Net Margin % Range Over the Past 10 Years
Min: -62.57 Med: -5.69 Max: 13.21
Current: -25.71
XKRX:383930's Net Margin % is ranked better than 60.51% of 942
companies
in the Biotechnology industry
Industry Median: -88.295
vs XKRX:383930: -25.71
DT&CRO Co (XKRX:383930) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
DT&CRO Co Net Margin % Related Terms
DT&CRO Co Net Margin % Historical Data
* Premium members only.
The historical data trend for DT&CRO Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:383930 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, DT&CRO Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DT&CRO Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DT&CRO Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where DT&CRO Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DT&CRO Co (XKRX:383930) has a Net Margin % of -136.04% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on DT&CRO Co and its competitors. According to the industry distribution chart, DT&CRO Co ranks #372 out of 942 companies in the Biotechnology industry, placing it in the top 39.5%.
Is DT&CRO Co's Net Margin % too high?
DT&CRO Co's current Net Margin % is -136.04%. Based on the distribution chart, DT&CRO Co ranks #372 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, DT&CRO Co has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does DT&CRO Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DT&CRO Co ranks #372 out of 942 companies for Net Margin %. This puts DT&CRO Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on DT&CRO Co and its competitors. DT&CRO Co's current Net Margin % is -136.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DT&CRO Co stock overvalued right now?
Based on GuruFocus' analysis, DT&CRO Co (XKRX:383930) is currently considered Possible Value Trap. The stock's GF Value™ is ₩5,038.48, compared to a current price of ₩1,710.00 — trading 66.1% below its estimated fair value. The current Net Margin % is -136.04%. DT&CRO Co's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For DT&CRO Co (XKRX:383930), the current Net Margin % is -136.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DT&CRO Co (XKRX:383930) Overvalued in 2026?
Based on GuruFocus' analysis, DT&CRO Co stock appears to be undervalued.
The current stock price of ₩1,710.00 is trading 66.1% below its estimated GF Value™ of ₩5,038.48.
GuruFocus considers DT&CRO Co to be Possible Value Trap.
Key valuation signals for XKRX:383930:
Net Margin %: -136.04%
GF Value™: ₩5,038.48 vs. price of ₩1,710.00 (66.1% below fair value)
No single metric tells the full story. See the XKRX:383930 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DT&CRO Co Ltd conducts a series of consigned research, from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics and medical devices, to analysis, bioactivity, clinical trials, and licensing consulting. provided as a service.
60GF Score
Get the complete analysis for XKRX:383930
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:383930 has been successfully added to your 
